South African Researchers: "Janssen Vaccine Booster Shot Prevents 84% of Hospitalization Risk from Omicron Infection"

[Image source=EPA Yonhap News]

[Asia Economy Reporter Jeon Jinyoung] A study has found that the second dose of the COVID-19 vaccine from Janssen, a pharmaceutical subsidiary of the US company Johnson & Johnson (J&J), can prevent 84% of hospitalizations caused by the Omicron variant infection.

According to overseas media on the 30th (local time), South African researchers surveyed 69,092 healthcare workers who received an additional dose of the Janssen vaccine from the 15th of last month to the 20th of this month and reached this conclusion. The related research has not yet undergone peer review.

The researchers stated that the hospitalization prevention efficacy of the Janssen vaccine booster shot was 63% immediately after vaccination, but increased to 84% after 14 days and 85% after 1 to 2 months.

Linda-Gail Becker, who participated in the study, said, "The study results confirmed that the original purpose of the COVID-19 vaccine?to protect people from severe deterioration and death?remains valid."

She added, "What the study showed is that perfect protection is achieved with two doses," but "I do not think it is possible to infer from this whether a third or fourth dose is necessary."

However, they acknowledged the limitation of this study in that the follow-up period for booster shot recipients was short.

This content was produced with the assistance of AI translation services.